# XTuit Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xtuit-pharmaceuticals

- Industry: Healthcare Specialists
- Headquarters: Waltham, US
- Website: www.xtuit.com/
- Total disclosed funding: $24M
- Latest round: Series A (Sep 2, 2016)
- Investors on record: 5

## About

XTuit Pharmaceuticals is a biotechnology company focused on developing innovative medicines for cancer treatment, leveraging proprietary technology to enhance therapeutic effectiveness and improve patient outcomes.Founded in 2011, XTuit Pharmaceuticals operates in Waltham, US, and focuses on advancing its proprietary drug development platform dedicated to oncology. The company has secured USD 6 mn in its Series A funding round in September 2016 from multiple investors including Omega Funds and Polaris Partners. The total amount raised to date is also USD 6 mn with a current company valuation of USD 37.668 mn.XTuit specializes in developing innovative therapeutics aimed at treating various cancers. The company is currently working on enhancing its drug pipeline which includes next-generation medicines designed to target specific cancer pathways, improving therapeutic efficacy and patient quality of life.XTuit Pharmaceuticals has a revenue model that is heavily aligned with its product development and potential market entry. Current financial details regarding revenue are not disclosed, as the company is primarily in the development phase focusing on drug testing and regulatory approvals.Looking ahead, XTuit Pharmaceuticals aims to expand its product pipeline with new therapeutics expected to enter clinical trials by late 2024. The company also plans to explore international markets, specifically targeting Europe and Asia for potential partnerships and market expansion by 2025. The recent funding of USD 6 mn will be allocated to further drug development, clinical trials, and scaling operational capabilities to support these initiatives.

## Funding rounds

- Series A, Sep 2, 2016, $6M — New Enterprise Associates, Polaris Partners, CTI Life Sciences, Arcus Ventures, Omega Funds
- Series A, Jun 10, 2016, $12M — New Enterprise Associates, Polaris Partners, CTI Life Sciences, Arcus Ventures, Omega Funds
- Series A, Dec 5, 2014, $4M — Polaris Partners
- Seed, Jan 17, 2014, $1.5M — Polaris Partners

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series A
- Arcus Ventures (https://capitalatlas.ai/funds/arcus-ventures) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A